• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inhibrx Biosciences, Inc. - Common Stock (NQ:INBX)

34.38 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 34.38
Bid (Size) 22.00 (1)
Ask (Size) 54.66 (1)
Prev. Close 34.38
Today's Range 34.38 - 34.38
52wk Range 10.80 - 37.53
Shares Outstanding N/A
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inhibrx Biosciences Beats Earnings
August 13, 2025
Via The Motley Fool
Topics Intellectual Property
Around $2M Bet On Franklin Resources? Check Out These 4 Stocks Executives Are Buying
September 03, 2024
 
Via Benzinga

Performance

YTD
+125.4%
+125.4%
1 Month
+26.5%
+26.5%
3 Month
+49.7%
+49.7%
6 Month
+189.4%
+189.4%
1 Year
+121.8%
+121.8%

More News

Read More
Over $7M Bet On This Health Care Stock? Check Out These 3 Stocks Executives Are Buying
August 27, 2024
Via Benzinga
INBX Stock Earnings: Inhibrx Beats EPS for Q1 2024
August 22, 2024
Via InvestorPlace
INBX Stock Earnings: Inhibrx Biosciences Beats EPS for Q2 2024
August 14, 2024
Via InvestorPlace
Top 4 Health Care Stocks That Are Preparing To Pump This Month
June 05, 2024
Via Benzinga
JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know
August 23, 2023
Via Benzinga
Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients
April 26, 2023
Via Benzinga
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
May 09, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
The NVDA Earnings Effect And What It Means For The Current Market Momentum
February 28, 2024
Via Talk Markets
Topics Stocks
Is The Stock Market Ready To Plunge? The Warning Signs Are Here...
February 21, 2024
Via Talk Markets
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX
February 10, 2024
From Kahn Swick & Foti, LLC
Via Business Wire
Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx
January 23, 2024
Via Investor's Business Daily
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders
January 23, 2024
From Halper Sadeh LLC
Via Business Wire
French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B
January 23, 2024
Via Benzinga
Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project
January 23, 2024
Via Benzinga
$1.5M Bet On Domo? Check Out These 3 Stocks Insiders Are Buying
August 31, 2023
Via Benzinga
Why NIO Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
August 29, 2023
Via Benzinga
Topics Intellectual Property
PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday
August 29, 2023
Via Benzinga
Topics Stocks
Inhibrx Stock Showing Improving Market Leadership; Earns 86 RS Rating
May 03, 2023
Via Investor's Business Daily
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
November 18, 2022
Via Benzinga
Inhibrx Posts Updated Efficacy, Safety Data From Expansion Cohorts Of Bone Cancer Candidate
November 16, 2022
Via Benzinga
$40 Million Bet On Inhibrx? 3 Stocks Insiders Are Buying
October 13, 2022
Via Benzinga
Stocks Reverse Gains After ADP Report
October 05, 2022
Via Talk Markets
R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing
October 05, 2022
Via FinancialNewsMedia
Topics Death

Frequently Asked Questions

Is Inhibrx Biosciences, Inc. - Common Stock publicly traded?
Yes, Inhibrx Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Inhibrx Biosciences, Inc. - Common Stock trade on?
Inhibrx Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inhibrx Biosciences, Inc. - Common Stock?
The ticker symbol for Inhibrx Biosciences, Inc. - Common Stock is INBX on the Nasdaq Stock Market
What is the current price of Inhibrx Biosciences, Inc. - Common Stock?
The current price of Inhibrx Biosciences, Inc. - Common Stock is 34.38
When was Inhibrx Biosciences, Inc. - Common Stock last traded?
The last trade of Inhibrx Biosciences, Inc. - Common Stock was at 10/13/25 04:00 PM ET
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+0.00 (0.00%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap